Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs
Entest BioMedical Inc.'s (OTCPINK: ENTB) Chairman and CEO David Koos discussed current and anticipated developments for the company's subsidiary, Zander Therapeutics Inc. Specifically, Zander Therapeutics is moving forward in the area of immunotherapy delivered through small molecule treatments. The company is the exclusive licensee for veterinary applications of Regen BioPharma's intellectual property for modulating the checkpoint NR2F6 to treat cancer and arthritis.
Zander Therapeutics :: Specializing in cutting edge therapies for animals
Founded in 2015 as a biotechnology company focused on veterinary medicine, specifically small molecule treatments for veterinary cancers, autoimmune diseases such as arthritis and other immunotherapies for specialty niche treatments. Zander is a subsidiary of Entest Group Inc. a fully reporting and trades publicly under the symbol: ETNI Focused on immuno-oncology, stem cell/cancer stem cell, gene silencing.
Copyright Zander Therapeutics, Inc. 2017